A 3-year interval is too short for re-screening women testing negative for human papillomavirus: a population-based cohort study

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 124, Issue 10, 2017, Pages 1585-1593

  Zorzi, M ^a   Frayle, H ^b   Rizzi, M ^b   Fedato, C ^c   Rugge, M ^a,d   Penon, M G ^e   Bertazzo, A ^e   Callegaro, S ^f   Campagnolo, M ^f   Ortu, F ^f   Del Mistro, A ^b   Baracco, Susanna ^g   Baboci, Lorena ^g   Amadori, Alberto ^g   Montaguti, Adriana ^g   Turrin, Anna ^g   Farruggio, Angelo ^g   Cocco, Patrizia ^g   Tumaini, Lucio ^g   Gerace, Pierfrancesco ^g   Borgato, Loretta ^g   Maso, Renata ^g   Bo, Patrizio ^g   Mari, Lucia ^g   Franzoi, Roberto ^g   Ferro, Antonio ^g   more..

^a Occupational Health Unit   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c Prevention and Public Health Unit   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e Local Health Unit 17 Monselice   (Italy)

^f Department of Prevention Local Health Unit 15 Alta padovana   (Italy)

^g NONE

Author keywords

Cervical cancer; CIN2+; HPV DNA test; screening interval

Indexed keywords

ADULT; AGE; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; COHORT ANALYSIS; COLPOSCOPY; EMERGENCY HEALTH SERVICE; FEMALE; FEMALE GENITAL TRACT CYTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INCIDENCE; ITALY; PATIENT PARTICIPATION; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; RESCREENING; RESCREENING INTERVAL; TIME; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; WOMEN'S HEALTH; COMPARATIVE STUDY; COMPLICATION; EARLY CANCER DIAGNOSIS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATIENT REFERRAL; PROCEDURES; STATISTICS AND NUMERICAL DATA; TIME FACTOR; UTERINE CERVIX; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADULT; CERVIX UTERI; COHORT STUDIES; COLPOSCOPY; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; REFERRAL AND CONSULTATION; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 85017663492     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.14575     Document Type: Article

References (28)

1. Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M, Ogilvie G, et al. Evidence regarding Human Papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30S:F88–99.
2. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
3. Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst 2014;106:1–4.
4. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014 Feb;8:524–32.
5. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 2015 Feb;136:189–97.
6. Canadian Task Force on Preventive Health Care, Dickinson J, Tsakonas E, Conner Gorber S, Lewin G, Shaw E, et al. Recommendations on screening for cervical cancer. CMAJ 2013;185:35–45.
7. Health Council of the Netherlands. Population screening for cervical cancer. The Hague: Health Council of the Netherlands, 2011; publication no. 2011/07E.
8. Ministero della Salute. Piano Nazionale della prevenzione 2010-2012. Azione centrale prioritaria concernente la “Definizione di documenti tecnici di sintesi delle evidenze scientifiche” a supporto della programmazione, monitoraggio e valutazione degli interventi di prevenzione oncologica nella popolazione a rischio. Ministero della Salute DGPRE 001068-P-14/01/2013, pagg. 1-22. [http://www.osservatorionazionalescreening.it/sites/default/files/allegati/Screening.pdf] Accessed 4 August 2015.
9. Moyer VA, U.S Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;156:880–91.
10. Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, et al. Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors.[Article in Italian]. Epidemiol Prev 2012;36:S1.
11. Ronco G, Arbyn M, Meijer CJLM, Snijders PJF, Cuzick J. Screening for cervical cancer with primary testing for human papillomavirus. S1. In: Anttila A, Arbyn M, De VH, Dillner J, Dillner L, Franceschi S, et al, editors. European Guidelines for Quality Assurance in Cervical Cancer Screening, 2nd edn, Supplements. Luxembourg: Office for Official Publications of the European Union, 2015. pp. 1–68.
12. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. Screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62:147–72.
13. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol 2015 Feb;136:178–82.
14. Del Mistro A, Frayle H, Ferro A, Callegaro S, Del Sole A, Stomeo A, et al. Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women. J Med Screen 2014;21:30–7.
15. Zorzi M, Del Mistro A, Farruggio A, de’ Bartolomeis L, Frayle-Salamanca H, Baboci L, et al. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening program: a population-based cohort study. BJOG 2013;120:1260–7.
16. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European guidelines for quality assurance in cervical cancer screening. Second edition-summary document. Ann Oncol 2010;21:448–58.
17. Coleman D, Day N, Douglas G, Farmery E, Lynge E, Philip J, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Europe against cancer program. Eur J Cancer 1993;29A(Suppl 4):S1–38.
18. Gruppo Italiano Screening Citologico (GISCi). Raccomandazioni sul test HR-HPV come test di screening primario e rivisitazione del ruolo del Pap test. Belluno: Evidenzia, 2010. 19p (Italian). [http://www.gisci.it/documenti/documenti_gisci/documento_hpv.pdf]. Accessed 22 march 2013.
19. Herbert A, Bergeron C, Wiener H, Schenck U, Klinkhamer P, Bulten J, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology. Cytopathology 2007;18:213–9.
20. Bruni L, Diaz M, Castellsagué Ferrer E, Bosch X, de Sanjosè S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010;202:1789–1799.
21. Pasquale L, Giorgi Rossi P, Carozzi F, Pedretti C, Ruggeri C, Scalvinoni V, et al. Cervical cancer screening with HPV testing in the Valcamonica (Italy) screening programme. J Med Screen 2015;22:38–48.
22. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764–72.
23. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al. Human Papillomavirus testing and liquid-based cytology in primary cervical screening: results at recruitment from the NTCC randomized controlled trial. JNCI 2006;98:765–74.
24. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, et al. Human Papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006;7:547–55.
25. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009;10:672–82.
26. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589–97.
27. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro AR, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249–57.
28. Vink MA, Bogaards JA, Meijer CJ, Berkhof J. Primary human papillomavirus DNA screening for cervical cancer prevention: can the screening interval be safely extended? Int J Cancer 2015;137:420–7.